Michael Makris Invites You to The Research Recap on FEIBA Use in Patients on Emicizumab
Michael Makris, Emeritus Professor of Haemostasis and Thrombosis at the University of Sheffield, Editor-in-Chief of RPTH Journal, reposted from ISTH on LinkedIn:
”If you treat persons with haemophilia and inhibitors, or if you are affected by the disease, we have a research recap that you may be interested in.
It relates to a paper and commentary published in the RPTH Journal on the use of FEIBA in patients on emicizumab (Hemlibra).
It will be interesting to discuss the issue with Drs Sidonio and Hermans.
Please join us next Tuesday at 11:15 ET, 16:15 UK and 17:15 Europe time.”
Quoting International Society on Thrombosis and Haemostasis( ISTH)‘s post:
”New RPTH Journal Research Recap! Dive into the latest insights from the article:
“Activated prothrombin complex concentrate in patients receiving emicizumab prophylaxis: from evidence to clinical practice.”
Join Robert Sidonio and Cedric Hermans (Lon,Edin) for an engaging discussion led by Michael Makris RPTH Editor-in-Chief.
Discover how emerging evidence is shaping clinical practice.
Don’t miss this expert-driven conversation!
Read ahead:
Register here.
This Research Recap is supported by an educational grant from TAKEDA PHARMACEUTICALS AMERICA, INC.”
Stay updated with Hemostasis Today.
-
Oct 17, 2025, 08:37Salome Mekhuzla Invites You to Join WHO Essential Medicines List 2025 Updates Webinar on Hemophilia and VWD
-
Oct 17, 2025, 08:36Plasma Protein Forum 2025: From Anti-D Plasma and Blood Supply Incentives to the Future of AI
-
Oct 17, 2025, 08:33Hossam El Benawi to Present Latest Mayo Clinic Insights on Left Ventricular Thrombus at AHA 2026
-
Oct 17, 2025, 08:32Brian O Mahony Invites You to Irish Haemophilia Society Webinar Series
-
Oct 17, 2025, 08:30Thomas Reiser Invites You to Take A Survey on AI and Machine Learning From ISTH
-
Oct 17, 2025, 09:00Shreya Agarwal: We Describe Patients With PLG Mutations Who Experienced Recurrent TMA
-
Oct 17, 2025, 08:41Review of Community-Based Stroke Rehabilitation in LMICs from Dominique Cadilhac's Team
-
Oct 16, 2025, 04:43Michael Makris Invites You to The Research Recap on FEIBA Use in Patients on Emicizumab
-
Oct 16, 2025, 04:41Suhasini Sil on Impact of AMBM Red Cell Transfusions in Improving Transfusion Outcomes
-
Oct 16, 2025, 04:37Hinde El Otmani's Team Explores Plasmin-Mediated Proteolysis of von Willebrand Factor in Acutely Ill Patients
-
Oct 14, 2025, 05:26Ryan C. Heniford: Every Thrombus Prevented Is a Patient Protected
-
Oct 13, 2025, 04:48Archil Jaliashvili showcases how BHOC builds on Hemopure’s success to revolutionize surgery and care
-
Oct 13, 2025, 02:46Flora Peyvandi: First Proposed Blood Test for Chronic Fatigue Syndrome - What Scientists Think
-
Oct 13, 2025, 02:44Silvio Maresca: Honored to be part of this international research project - ThrombUS+
-
Oct 10, 2025, 12:25Robert Lewis: T Cells Are Wonderful - But They Can't Do Everything
-
Oct 17, 2025, 08:52Erica Sparkenbaugh: Shout Out to My Doctoral Student Kylie Hutchison for Her Outstanding Oral Presentation
-
Oct 17, 2025, 08:45Shamee Shastry Shares Lean and Six Sigma in Transfusion Medicine Training Program's Success
-
Oct 16, 2025, 04:44Giles Platford Discusses Strengthening the Plasma Ecosystem for Patients Worldwide at PPF2025
-
Oct 16, 2025, 04:27Ranjeet Ajmani: Southeast Asia - 25% of The Global Population Contributes Less than 2% of The Global Plasma Supply
-
Oct 15, 2025, 05:59Courtney Lawrence: I've Got A Place at American Red Cross for You!